v3.26.1
REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS (Details 1) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenues, net $ 87,970   $ 178,238   $ 167,038 $ 313,137
Research and development 712,384   296,860   1,064,717 458,779
Selling, general and administrative 686,323   1,223,321   1,477,505 2,109,404
Total operating expenses 1,553,508   1,592,158   2,739,776 2,665,003
Loss from operations (1,465,538)   (1,413,920)   (2,572,738) (2,351,866)
Interest expense - related parties (138,597)   (164,371)   (274,045) (324,499)
Interest expense, net (30,048)   (36,686)   (61,089) (124,169)
Loss on settlement of debt (47,000)   (55,000)   (147,000) (187,514)
Grant income 679,477   154,270   1,042,074 568,249
Total other income 463,832   36,644   559,940 122,826
Loss before provision for income taxes (1,001,706)   (1,377,276)   (2,012,798) (2,229,040)
Income taxes 0   0   0 0
Net loss (1,001,706) $ (1,011,092) (1,377,276) $ (851,764) (2,012,798) (2,229,040)
Net loss attributable to the non-controlling interest (36,932)   (143,858)   (102,188) (154,215)
Net loss attributable to BioCorRx Inc. $ (964,774)   $ (1,233,418)   $ (1,910,610) $ (2,074,825)
Net loss per common share, basic and diluted $ (0.03)   $ (0.07)   $ (0.07) $ (0.13)
Weighted average number of common shares outstanding, basic and diluted 29,219,541   17,011,680   27,419,591 16,058,504
Interest expense - related party $ 138,597   $ 164,371   $ 274,045 $ 324,499
Interest expense $ 30,048   $ 36,686   $ 61,089 $ 124,169
As Revised [Member]            
Revenues, net   79,068        
Cost of goods sold   25,184        
Research and development   352,333        
Selling, general and administrative   791,182        
Impairment of intellectual property   6,374        
Depreciation and amortization   11,195        
Total operating expenses   1,186,268        
Loss from operations   (1,107,200)        
Interest expense - related parties   (135,448)        
Interest expense, net   (31,041)        
Loss on settlement of debt   (100,000)        
Grant income   362,597        
Total other income   96,108        
Loss before provision for income taxes   (1,011,092)        
Income taxes   0        
Net loss   (1,011,092)        
Net loss attributable to the non-controlling interest   65,256        
Net loss attributable to BioCorRx Inc.   $ (945,836)        
Net loss per common share, basic and diluted   $ (0.04)        
Weighted average number of common shares outstanding, basic and diluted   25,599,642        
Interest expense - related party   $ 135,448        
Interest expense   31,041        
Revision [Member]            
Revenues, net   (135,471)        
Cost of goods sold   0        
Research and development   0        
Selling, general and administrative   15,729        
Impairment of intellectual property   0        
Depreciation and amortization   0        
Total operating expenses   15,729        
Loss from operations   (151,200)        
Interest expense - related parties   0        
Interest expense, net   0        
Loss on settlement of debt   0        
Grant income   0        
Total other income   0        
Loss before provision for income taxes   (151,200)        
Income taxes   0        
Net loss   (151,200)        
Net loss attributable to the non-controlling interest   36,591        
Net loss attributable to BioCorRx Inc.   $ (114,609)        
Net loss per common share, basic and diluted   $ (0.01)        
Weighted average number of common shares outstanding, basic and diluted   0        
Interest expense - related party   $ 0        
Interest expense   0        
As Reported [Member]            
Revenues, net   214,539        
Cost of goods sold   25,184        
Research and development   352,333        
Selling, general and administrative   775,453        
Impairment of intellectual property   6,374        
Depreciation and amortization   11,195        
Total operating expenses   1,170,539        
Loss from operations   (956,000)        
Interest expense - related parties   (135,448)        
Interest expense, net   (31,041)        
Loss on settlement of debt   (100,000)        
Grant income   362,597        
Total other income   96,108        
Loss before provision for income taxes   (859,892)        
Income taxes   0        
Net loss   (859,892)        
Net loss attributable to the non-controlling interest   28,665        
Net loss attributable to BioCorRx Inc.   $ (831,227)        
Net loss per common share, basic and diluted   $ (0.03)        
Weighted average number of common shares outstanding, basic and diluted   25,599,642        
Interest expense - related party   $ 135,448        
Interest expense   $ 31,041